A61K 51/106
The tumor cell being from kidney or bladder
Official title: {the tumor cell being from kidney or bladder}
A61K51/106 (The tumor cell being from kidney or bladder) appears on 47 US grants and 66 published applications in this corpus.
Search patents in A61K- Granted patents
- 47
- Published applications
- 66
- Assignees
- 36
- Inventors
- 100
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 4 |
| 2003 | 1 | 4 |
| 2004 | 3 | 1 |
| 2005 | 2 | 6 |
| 2006 | 1 | 2 |
| 2007 | 0 | 0 |
| 2008 | 3 | 1 |
| 2009 | 5 | 4 |
| 2010 | 0 | 2 |
| 2011 | 2 | 2 |
| 2012 | 2 | 4 |
| 2013 | 1 | 5 |
| 2014 | 2 | 2 |
| 2015 | 3 | 1 |
| 2016 | 0 | 1 |
| 2017 | 2 | 5 |
| 2018 | 0 | 0 |
| 2019 | 4 | 4 |
| 2020 | 3 | 7 |
| 2021 | 2 | 1 |
| 2022 | 2 | 1 |
| 2023 | 1 | 2 |
| 2024 | 1 | 4 |
| 2025 | 0 | 0 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals3 Mar 2026US 12,565,506 B2Clarity Pharmaceuticals Ltd
- Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals20 Feb 2024US 11,905,301 B2Clarity Pharmaceuticals Ltd
- Anti-human MUC1 antibody Fab fragment20 Jun 2023US 11,679,166 B2Astellas Pharma Inc.
- Branched discrete PEG constructs22 Nov 2022US 11,505,525 B2Quanta BioDesign, Ltd.
- Antibodies and molecules derived therefrom that bind to STEAP-1 proteins2 Aug 2022US 11,401,347 B2Agensys, Inc.
- Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals6 Aug 2026US 2026/0226078 A1Clarity Pharmaceuticals Ltd
- Kidney targeting antibodies26 Feb 2026US 2026/0055180 A1Abdera Therapeutics Inc.
- Combination radiotherapy14 Nov 2024US 2024/0374764 A1Merck Patent GmbH
- Treatment of bladder cancer with radiolabeled antibodies targeting cdcp17 Nov 2024US 2024/0366814 A1The Regents of the University of California
- Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof22 Aug 2024US 2024/0277878 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- Method for selection of primate tumor-associated antigens suitable as in vivo targets for antibodies68US 5,049,373 AUniversity of Pittsburgh · 1991
- Monoclonal antibody specifically reactive to surface of human prostatic epithelial cells47US 5,055,404 A1991
- Nucleic acids encoding prostate stem cell antigen41US 6,979,730 B2The Regents of the University of California · 2005
- Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same30US 5,153,118 AEastern Virginia Medical Authority · 1992
- Antibodies and related molecules that bind to PSCA proteins29US 7,595,379 B2Agensys, Inc. · 2009